Budget Amount *help |
¥42,120,000 (Direct Cost: ¥32,400,000、Indirect Cost: ¥9,720,000)
Fiscal Year 2018: ¥9,880,000 (Direct Cost: ¥7,600,000、Indirect Cost: ¥2,280,000)
Fiscal Year 2017: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2016: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2015: ¥10,920,000 (Direct Cost: ¥8,400,000、Indirect Cost: ¥2,520,000)
|
Outline of Final Research Achievements |
We analyzed the association of HLA with clinical outcome in 536 HIV-1 subtype A/E-infected treatment-naive Vietnamese and found that HLA-C*12:02 and HLA-A*29:01-B*07:05-C*15:05 were protective allele and detrimental haplotype, respectively. We further analyzed the sequences of HIV-1 in these individuals and identified 303 HLA-associated mutations which are candidates of CTL escape mutations. We analyzed ART treatment patients and found 90% success rate of treatment for 42 months. Out of 26 patients with treatment failure, 5 patients were infected with HIV-1 having drug resistance mutations in protease. We also found a significant association of TPVr treatment with hyperlipidemia in the treatment patients.
|